Important Reminder for Picard Medical Investors Regarding Securities Class Action Deadline

Key Reminder for Picard Medical Investors

In a crucial announcement, Faruqi & Faruqi, LLP, a prominent national securities law firm, is drawing attention to an upcoming deadline that all investors in Picard Medical, Inc. (NYSE PMI) should be aware of. The firm is currently investigating potential claims against Picard Medical and reminds affected investors that the deadline to seek the role of lead plaintiff in a federal securities class action is set for April 13, 2026.

Background of the Issues

The allegations against Picard Medical center on accusations of violation of federal securities laws, stemming from misleading statements made by the company and its executives. Reports indicate that Picard was involved in a fraudulent stock promotion scheme, which included the use of social media to disseminate misinformation. Furthermore, it has been suggested that insiders or affiliates might have employed offshore or nominee accounts to facilitate coordinated share dumping during a price inflation campaign. Consequently, significant discrepancies in Picard’s public statements and the actual trading activities have come to light.

This troubling scenario became particularly evident when, on October 24, 2025, shares of Picard Medical plummeted from $13.20 to $5.31, marking nearly a 60% decrease in value in a single trading day. Such a drastic decline is alarming and raises serious concerns about the company’s practices and investor rights.

Legal Implications

As is customary in such circumstances, the court will appoint a lead plaintiff, which will be the investor with the most significant financial interest in the case who also fulfills the criteria of being both adequate and typical of the class members affected. Should any member of the class wish to take an active role in the litigation process, they may move the court to serve in this capacity through their chosen counsel. It's crucial to note that whether one participates as a lead plaintiff or remains inactive does not affect their ability to share in any recovery.

Given these developments, Faruqi & Faruqi is also calling for anyone with additional information regarding Picard Medical’s potential misconduct to come forward. This includes whistleblowers, former employees, and shareholders.

Taking Action

Investors who have experienced losses exceeding $50,000 between September 2, 2025, and October 31, 2025, are strongly encouraged to reach out to Faruqi & Faruqi partner Josh Wilson for a consultation on their legal options. Interested parties can contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

For those seeking further information regarding the specific class action against Picard Medical, additional details are available at Faruqi & Faruqi's official website. Quick responses are encouraged as the April deadline approaches, underscoring the urgency of the situation for affected investors.

Conclusion

With legal repercussions looming and a pressing deadline ahead, it is imperative for Picard Medical investors to remain informed and proactive. This case highlights the importance of investor rights and the need for transparency in corporate finances. Faruqi & Faruqi will continue to monitor developments closely and provide support to those affected as the situation unfolds.

Stay connected for further updates by following Faruqi & Faruqi on LinkedIn and other social media platforms.